Phase 3 Breast Cancer Trial, Recruiting NCT06781996 Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Condition: Breast Cancer
Back to Breast Cancer

Phase 3 Breast Cancer Trial, Recruiting

NCT06781996
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been confirmed through a biopsy or tissue test to have hormone receptor-positive (HR+) invasive breast cancer, meaning the cancer responds to hormones like oestrogen and/or progesterone
  • People diagnosed with early-stage breast cancer (stage I to III) with no signs that the cancer has spread to other parts of the body or come back locally
  • People who have a medical reason to be taking hormone-blocking treatment (such as tamoxifen or aromatase inhibitors), with or without other targeted medicines
  • People who are already actively taking hormone-blocking treatment for their breast cancer at the time of joining the trial
  • People who are experiencing side effects from their current hormone-blocking treatment
  • People aged 18 or older
  • People whose general physical ability to carry out daily activities falls within a certain functional range (confirm with trial site)
  • People who own and use a smartphone
  • People who are able and willing to follow the study visits and procedures as required
  • People who are covered by a social security or health insurance system
  • People who can easily read and understand French
  • People who have had breast reconstruction may still be eligible to participate
  • Men with breast cancer may be eligible to join

Who may not be able to join:

  • People with serious cognitive (thinking or memory) difficulties or severe mental health conditions that, in the medical team's opinion, would make it difficult to follow the study requirements
  • People who are under legal guardianship, have had their freedom restricted by a court or administrative decision, or are unable to give their own consent
  • People who are already taking part in another behavioural intervention trial at the time of enrolling in this study
  • People whose side effects from hormone-blocking treatment are caused by a separate, treatable physical condition — such as anaemia, an imbalance of minerals in the body, an infection, kidney problems, or a hormonal condition like an underactive thyroid — according to the doctor's judgement

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ines VAZ-LUIS, MD, Gustave Roussy, Cancer Campus, Grand Paris

Phone: +33142114211

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Registry
ClinicalTrials.gov
Start date
9 September 2025
Est. completion
15 March 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

To determine the efficacy of a personalized approach, consisting of a multi-component, interventional mobile application in addition to standard of care, compared with standard care alone in improving quality of life (QOL) after 12 weeks.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov